Skip to Content

Join the 'Bextra' group to help and get support from people like you.

Bextra News

Giving the 'Green Light' to Migraine Relief

Posted 17 May 2016 by Drugs.com

TUESDAY, May 17, 2016 – A new study sheds light – literally – on a potential means of easing migraine pain. Researchers in Boston exposed 69 migraine patients to different colors of light. They found that while blue light exacerbated headache pain, a narrow spectrum of low-intensity green light significantly reduced light sensitivity. In some cases, this green light also reduced migraine pain by about 20 percent, the researchers found. They noted that migraine headache affects nearly 15 percent of people worldwide, and a frequent symptom of migraine is light sensitivity, also known as photophobia. "Although photophobia is not usually as incapacitating as headache pain itself, the inability to endure light can be disabling," study author Rami Burstein, of Beth Israel Deaconess Medical Center in Boston, said in a medical center news release. "More than 80 percent of migraine attacks ... Read more

Related support groups: Migraine, Celebrex, Fioricet, Excedrin, Imitrex, Tylenol PM, Sumatriptan, Maxalt, Fiorinal, Seasonal Affective Disorder, Excedrin Migraine, Cafergot, Zomig, Advil PM, Relpax, Treximet, Midrin, Vioxx, Ergotamine, Esgic

X-Rays May Miss Hip Arthritis, Study Finds

Posted 10 Dec 2015 by Drugs.com

THURSDAY, Dec. 10, 2015 – X-rays don't detect hip arthritis in many patients, resulting in delayed diagnosis and treatment, researchers report. The researchers looked at information from almost 4,500 Americans taking part in two arthritis studies. In one study, only 16 percent of patients with hip pain had X-ray evidence of osteoarthritis in the hip and only 21 percent of those with X-ray evidence of arthritis had hip pain. In the other study, the rates were 9 percent and 24 percent, respectively, according to the findings reported recently in the journal BMJ. "The majority of older subjects with high suspicion for clinical hip osteoarthritis did not have radiographic hip osteoarthritis, suggesting that many older persons with hip osteoarthritis might be missed if diagnosticians relied on hip radiographs to determine if hip pain was due to osteoarthritis," said study corresponding ... Read more

Related support groups: Pain, Suboxone, Oxycodone, Hydrocodone, Methadone, Percocet, Tramadol, Chronic Pain, OxyContin, Vicodin, Norco, Fentanyl, Morphine, Osteoarthritis, Codeine, Lortab, Tylenol, Opana, Ibuprofen, Subutex

Certain Painkillers Tied to Raised Risk of Death After Stroke

Posted 5 Nov 2014 by Drugs.com

WEDNESDAY, Nov. 5, 2014 – Arthritis pain relievers known as COX-2 inhibitors, including Celebrex and Lodine, are associated with an increased risk of dying within a month after a stroke, according to a new study. "This large study from Denmark adds to the prior concerns about COX-2 inhibitors and stroke risks," said Dr. Ralph Sacco, chairman of neurology at the University of Miami Miller School of Medicine. "Patients at high risk for stroke should be cautious about taking such medications and should consult their physicians as to the best medications to treat inflammation and pain," Sacco said. However, while the study found an association between use of these painkillers and death in stroke patients, it did not prove cause-and-effect. Other types of nonsteroidal anti-inflammatory painkillers (NSAIDs) – including ibuprofen (Advil, Motrin) and naproxen (Aleve) – weren't linked to an ... Read more

Related support groups: Celebrex, Etodolac, Lodine, Vioxx, Celecoxib, Lodine XL, Valdecoxib, Bextra, Rofecoxib

Common Painkillers May Help Prevent Skin Cancer: Study

Posted 29 May 2012 by Drugs.com

TUESDAY, May 29 – Taking nonsteroidal anti-inflammatory drugs (NSAIDs) – which include medicine cabinet staples such as aspirin, Motrin and Aleve – appears to significantly lower the risk for developing several major forms of skin cancer, a new Danish study reveals. What's more, the apparent protective impact of both prescription and nonprescription NSAIDs on skin cancer risk seems to be stronger the longer someone takes them. Over-the-counter NSAIDs are used to control pain, fever and swelling. NSAIDs also include prescription medicines called COX-2 enzyme inhibitors, such as Celebrex (celecoxib). "Our study showed that users of common painkillers, known as NSAIDs, have a lower risk of the three major types of skin cancer, [including] malignant melanoma, basal cell carcinoma and squamous cell carcinoma," said study lead author, Sigrun Alba Johannesdottir, at the department of ... Read more

Related support groups: Aspirin, Ibuprofen, Naproxen, Meloxicam, Celebrex, Diclofenac, Advil, Voltaren, Aleve, Mobic, Motrin, Indomethacin, Basal Cell Carcinoma, Toradol, Etodolac, Nabumetone, Skin Cancer, Flector, Arthrotec, Ketorolac

Scientists Spot How Cox-2 Painkillers Raise Heart Risks

Posted 2 May 2012 by Drugs.com

WEDNESDAY, May 2 – New research has uncovered how some cox-2 painkillers increase the risk for both heart attacks and stroke. The once popular cox-2 drugs, Vioxx and Bextra, were pulled off the market in 2004 and 2005, respectively, after research showed that both raised the chances of cardiovascular trouble. Meanwhile, Celebrex, a painkiller in the same drug class that remains on the market, carries a "black box" warning alerting patients to potential heart risks. Now, a team of scientists from the University of Pennsylvania in Philadelphia say that, although cox-2 inhibitors are very good at inhibiting the workings of the cox-2 enzyme – and thereby easing pain – they also throw off the cardiovascular system's delicate balance by inhibiting an enzyme that relaxes blood vessels and guards against clotting. "It's really about a rock and a hard place," said Dr. Christopher Cannon, a ... Read more

Related support groups: Celebrex, Vioxx, Celecoxib, Valdecoxib, Bextra, Rofecoxib

Some Pain Meds Riskier for Cardiac Patients Than Others, Study Suggests

Posted 28 Sep 2011 by Drugs.com

From Canadian Press DataFile (September 27, 2011) By Helen Branswell TORONTO – A new study suggests some commonly consumed pain medications are riskier than others when used by people with cardiovascular problems. The research suggests a couple of the drugs carry the same level of risk as Vioxx, which was taken off the market in 2004 over heart health concerns. Senior author Dr. David Henry says the increased risk from this class of drugs is not significant for the average healthy individual taking the drugs occasionally. But he says the risk profile changes in people who have already had a heart attack or who are at risk of cardiovascular events because they have diabetes, high blood pressure or a family history of heart disease. "So we're really worried about people who might have an annual risk of maybe five per cent," said Henry, who is CEO of the Toronto-based Institute for ... Read more

Related support groups: Aspirin, Ibuprofen, Naproxen, Meloxicam, Celebrex, Advil, Diclofenac, Voltaren, Aleve, Mobic, Motrin, Indomethacin, Toradol, Etodolac, Nabumetone, Flector, Ketorolac, Arthrotec, Naprosyn, Vimovo

Painkillers May Raise Risk of Dangerous Heart Flutter

Posted 5 Jul 2011 by Drugs.com

TUESDAY, July 5 – A new study finds that painkillers widely used to treat inflammation are associated with an increased risk of atrial fibrillation, a heart rhythm disorder connected with a raised risk of stroke, heart failure and death. Previous research has linked non-steroidal anti-inflammatory drugs (NSAIDs) and newer anti-inflammatory medications known as cox-2 inhibitors to an increased risk for heart attacks and strokes, but this is the first study to link the painkillers with atrial fibrillation. Danish researchers looked at 32,602 patients who had a first diagnosis of atrial fibrillation between 1999 and 2008. Each of those patients was compared with 10 age and gender-matched controls from the general population in Denmark. The results showed that use of these medications was associated with an increased risk of atrial fibrillation. The link was strongest among new users of ... Read more

Related support groups: Ibuprofen, Naproxen, Atrial Fibrillation, Meloxicam, Celebrex, Advil, Diclofenac, Voltaren, Aleve, Mobic, Motrin, Indomethacin, Toradol, Etodolac, Nabumetone, Flector, Arthrotec, Ketorolac, Vimovo, Naprosyn

FDA Medwatch Alert: Bextra (valdecoxib)

Posted 7 Apr 2005 by Drugs.com

After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: * The lack of adequate data on the cardiovascular safety of long-term use of Bextra, along with the increased risk of adverse cardiovascular (CV) events in short-term coronary artery bypass surgery (CABG) trials that FDA believes may be relevant to chronic use. * Reports of serious and potentially life-threatening skin reactions, including deaths, in patients using Bextra. The risk of these reactions in individual patients is unpredictable, occurring in patients with and without a prior history of sulfa allergy, and after both short- and long-term use. * Lack of any demonstrated advantages for Bextra compared with other NSAIDs. Patients currently taking Bextra should contact their physicians to ... Read more

Related support groups: Bextra

FDA Medwatch Alert: Bextra (valdecoxib)

Posted 15 Jun 2005 by Drugs.com

FDA has requested that sponsors of all non-steroidal anti-inflammatory drugs (NSAID) make labeling changes to their products. FDA recommended proposed labeling for both the prescription and over-the-counter (OTC) NSAIDs and a medication guide for the entire class of prescription products. All sponsors of marketed prescription NSAIDs, including Celebrex (celecoxib), a COX-2 selective NSAID, have been asked to revise the labeling (package insert) for their products to include a boxed warning, highlighting the potential for increased risk of cardiovascular (CV) events and the well described, serious, potential life-threatening gastrointestinal (GI) bleeding associated with their use. FDA regulation 21CFR 208 requires a Medication Guide to be provided with each prescription that is dispensed for products that FDA determines pose a serious and significant public health concern. [June 15, ... Read more

Related support groups: Bextra

FDA Medwatch Alert: Bextra (valdecoxib)

Posted 10 Dec 2004 by Drugs.com

The FDA announced important new information on side effects associated with the use of Bextra, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of osteoarthritis, rheumatoid arthritis and dysmenorrhea (menstrual pain). A "boxed" warning, strengthening previous warnings about the risk of life-threatening skin reactions, and a new bolded warning contraindicating the use of Bextra in patients undergoing coronary artery bypass graft (CABG) surgery were added to the label.[December 9, 2004 - Talk Paper - FDA][December 9, 2004 - Questions and Answers - FDA][November, 2004 - Label - Pfizer] Read more

Related support groups: Bextra

FDA Medwatch Alert: Bextra (valdecoxib)

Posted 15 Nov 2002 by Drugs.com

FDA and Pharmacia/Pfizer strengthened the CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS sections of the prescribing information. In postmarketing experience, rare reports of hypersensitivity reactions (i.e, anaphylatic reactions and angioedema) and skin reactions, including cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme, have been received. These cases, some of which were serious/life threatening, have occured in patients with and without a history of allergic type reations to sulfonamides.[November 2002 Letter - Pharmacia/Pfizer] PDF Format[November 2002 Talk Paper - FDA][October 2002 Full, Revised Label, changes highlighted - Pharmacia/Pfizer] Read more

Related support groups: Bextra

FDA Medwatch Alert: COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Posted 15 Jun 2005 by Drugs.com

After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: * The lack of adequate data on the cardiovascular safety of long-term use of Bextra, along with the increased risk of adverse cardiovascular (CV) events in short-term coronary artery bypass surgery (CABG) trials that FDA believes may be relevant to chronic use. * Reports of serious and potentially life-threatening skin reactions, including deaths, in patients using Bextra. The risk of these reactions in individual patients is unpredictable, occurring in patients with and without a prior history of sulfa allergy, and after both short- and long-term use. * Lack of any demonstrated advantages for Bextra compared with other NSAIDs. Patients currently taking Bextra should contact their physicians to ... Read more

Related support groups: Celebrex, Advil, Mobic, Toradol, Lodine, Relafen, Vioxx, Cataflam, Indocin, Feldene, Daypro, Ponstel, Ansaid, Dolobid, Nalfon, Clinoril, Bextra, Actron, Aflaxen, Tolectin

Ask a Question

Further Information

Related Condition Support Groups

Pain, Rheumatoid Arthritis, Period Pain, Dysmenorrhea, Osteoarthritis

Bextra Patient Information at Drugs.com